Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "NEERI"

505 News Found

Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants
News | September 24, 2025

Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants

Relonchem receives marketing authorization for Moxonidine tablets


AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
Drug Approval | September 24, 2025

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population


Roche to acquire 89bio in $3.5B deal
News | September 20, 2025

Roche to acquire 89bio in $3.5B deal

Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins


GAIASO appoints Dr. Tracey Brown as CEO
People | September 16, 2025

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,


MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025
News | September 16, 2025

MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025

Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem


VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications
News | September 12, 2025

VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications

CRISPR-based detection enables highly specific molecular recognition


Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing
Biotech | September 12, 2025

Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing

Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients


iRegene Therapeutics secures series B+ financing
Biotech | September 12, 2025

iRegene Therapeutics secures series B+ financing

NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation